Ulrika Yngve

Medicinal Chemistry-Lead Identification

Key publications

G. Popova, M. J. G. W. Ladds, L. Johansson, A. Saleh, J. Larsson, L. Sandberg, S. Sahlberg S, W Qian, H. Gullberg, A-L Gustavsson, M. Haraldsson, D. Lane, U. Yngve, S. Lain.
Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
Journal of Medicinal Chemistry 63 (2020) 3915–3934. https://doi.org/10.1021/acs.jmedchem.9b01658

P. Nordeman, U. Yngve, H. Wilking, S-Å. Gustafsson, J. Eriksson, G. Antoni
Automated GMP-production of α-[11C]methyl-L-tryptophan using a tracer production system (TPS),
J Label Compd Radiopharm. (2018), DOI: 10.1002/jlcr.3648

M. Ladds, I. van Leeuwen, C. Drummond, S. Chu, A. Healy, G. Popova, A. Pastor Fernández, T. Mollick, S. Darekar, S. Sedimbi, M. Nekulova, M. Sachweh, J. Campbell, M. Higgins, C. Tuck, M. Popa, M. Mayoral Safont, P. Gelebart, Z. Fandalyuk, A. Thompson, R. Svensson, A-L. Gustavsson, L. Johansson, K. Färnegårdh, U. Yngve, A. Saleh, M. Haraldsson, A. D’Hollander, M. Franco, Y. Zhao, M. Håkansson, B. Walse, K. Larsson, E. Peat, V. Pelechano, J. Lunec, B. Vojtesek, M. Carmena, W. Earnshaw, A. McCarthy, N. Westwood, M. Henriksson, D. Lane, R. Bhatia, E. McCormack, S. Lain
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
Nature Com. 9 (2018) 1107, DOI: 10.1038/s41467-018-03441-3.

X. T. Fang, J. Eriksson, G. Antoni, U. Yngve, L. Cato, L. Lannfelt, D. Sehlin, S. Syvaenen
Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [11C]ABP688 PET imaging and ex vivo immunoblotting
Neuropharmacology 113 (2017) 293-300, DOI: 10.1016/j.neuropharm.2016.10.009

U. Yngve *, K. Paulsen, I. Macsari, M. Sundström, E. Santangelo, C. Linde, K. Bogar, F. Lake, Y. Besidski, J. Malmborg, K. Strömberg, P. Appelkvist, A-C. Radesäter, F. Olsson, D. Bergström, R. Klintenberg, P. I. Arvidsson
Triazolopyrimidinones as γ-Secretase Modulators: Structure-Activity Relationship, Modulator Profile, and in vivo Profiling
MedChemComm 4 (2013) 422-431, DOI:10.1039/C2MD20312J

Ulrika Yngve

The Drug discovery and development platform has the mission to turn academic projects into innovations. With the capabilities to design and synthesize drug-like compounds, the medicinal chemistry units take the project from a lead generation strategy to a compound suitable for a proof-of-concept in your selected animal model.

In addition, we are implementing the use of DNA encoded libraries as a way to identify novel starting points in our drug discovery projects. This project is lead by Johan Wannberg. During 2024, Nathan Poongavanam joined the group as an expert in machine learning in drug discovery. 

Group Members

Johanna Larsson
Vasanthanathan (Nathan) Poongavanam
Johan Wannberg

Last updated: 2025-01-16

Content Responsible: David Gotthold(david.gotthold@scilifelab.se)